茚地那韦和洛匹那韦在人类免疫缺陷病毒感染女性生殖器分泌物中的差异扩散。
Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.
作者信息
Launay Odile, Tod Michel, Louchahi Kamel, Belarbi Linda, Bouchaud Olivier, Mémain Nathalie, Petitjean Olivier, Robineau Michel, Guillevin Loïc, Lortholary Olivier
机构信息
Fédération de Médecine Interne, Maladies Infectieuses et Tropicales and UPRES EA 3409, Université Paris-Nord, Bobigny, France.
出版信息
Antimicrob Agents Chemother. 2004 Feb;48(2):632-4. doi: 10.1128/AAC.48.2.632-634.2004.
Abstract
Plasma and cervicovaginal secretion (CVS) samples were collected from 19 human immunodeficiency virus type 1-infected women on lopinavir- or indinavir-containing regimens. Lopinavir and indinavir were detectable in 29 and 93% of CVS samples, respectively, a finding that may be ascribed to these drugs' differences in protein binding and pK(a). The relationship between lopinavir and indinavir pharmacodynamics and viral evolution in the female genital tract should be assessed over time.
摘要
从19名接受含洛匹那韦或茚地那韦治疗方案的1型人类免疫缺陷病毒感染女性中采集了血浆和宫颈阴道分泌物（CVS）样本。分别在29%和93%的CVS样本中检测到了洛匹那韦和茚地那韦，这一发现可能归因于这些药物在蛋白结合和pK(a)方面的差异。应随着时间推移评估洛匹那韦和茚地那韦的药效学与女性生殖道病毒进化之间的关系。
相似文献
1
Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.
Antimicrob Agents Chemother. 2004 Feb;48(2):632-4. doi: 10.1128/AAC.48.2.632-634.2004.
2
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
J Antimicrob Chemother. 2004 Aug;54(2):498-502. doi: 10.1093/jac/dkh357. Epub 2004 Jul 14.
3
Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
HIV Clin Trials. 2002 Jan-Feb;3(1):27-35. doi: 10.1310/WMWL-6W9Y-PXV2-X148.
4
Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.
Ther Drug Monit. 2005 Dec;27(6):779-81. doi: 10.1097/01.ftd.0000177665.34845.fa.
5
Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.
J Antimicrob Chemother. 2006 Aug;58(2):393-400. doi: 10.1093/jac/dkl238. Epub 2006 Jun 7.
6
Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
Eur J Med Res. 2006 Jun 30;11(6):236-44.
7
Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Aug 5;775(2):225-30. doi: 10.1016/s1570-0232(02)00295-7.
8
Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32. doi: 10.1128/AAC.46.9.2926-2932.2002.
9
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Clin Pharmacol Ther. 2006 Oct;80(4):307-18. doi: 10.1016/j.clpt.2006.06.006.
10
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
HIV Med. 2011 Mar;12(3):166-73. doi: 10.1111/j.1468-1293.2010.00865.x. Epub 2010 Aug 18.
引用本文的文献
1
Pharmacokinetics of antiretrovirals in mucosal tissue.
Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):893-905. doi: 10.1517/17425255.2015.1027682. Epub 2015 Mar 22.
2
Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.
Clin Pharmacokinet. 2014 Jul;53(7):611-24. doi: 10.1007/s40262-014-0148-z.
3
Antiretroviral pharmacology in mucosal tissues.
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2(0 2):S240-7. doi: 10.1097/QAI.0b013e3182986ff8.
4
Antiretroviral bioanalysis methods of tissues and body biofluids.
Bioanalysis. 2013 Feb;5(3):351-68. doi: 10.4155/bio.12.319.
5
Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.
Antimicrob Agents Chemother. 2012 May;56(5):2283-9. doi: 10.1128/AAC.00166-12. Epub 2012 Feb 21.
本文引用的文献
1
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
AIDS. 2003 Jan 24;17(2):209-14. doi: 10.1097/00002030-200301240-00011.
2
Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother. 2003 Jan;47(1):238-43. doi: 10.1128/AAC.47.1.238-243.2003.
3
Limited penetration of lopinavir into seminal plasma of HIV-1-infected men.
AIDS. 2002 Aug 16;16(12):1698-700. doi: 10.1097/00002030-200208160-00023.
4
Determinants of HIV-1 shedding in the genital tract of women.
Lancet. 2001 Nov 10;358(9293):1593-601. doi: 10.1016/S0140-6736(01)06653-3.
5
Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir.
J Antimicrob Chemother. 2001 Sep;48(3):351-4. doi: 10.1093/jac/48.3.351.
6
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.
Ther Drug Monit. 2001 Feb;23(1):56-60. doi: 10.1097/00007691-200102000-00011.
7
Antiretroviral drug concentrations in semen of HIV-1 infected men.
Sex Transm Infect. 2001 Feb;77(1):4-11. doi: 10.1136/sti.77.1.4.
8
Lopinavir.
Drugs. 2000 Dec;60(6):1371-9; discussion 1380-1. doi: 10.2165/00003495-200060060-00009.
9
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
AIDS. 2000 Jun 16;14(9):1187-94. doi: 10.1097/00002030-200006160-00016.
10
Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.
J Infect Dis. 2000 Jul;182(1):112-22. doi: 10.1086/315679. Epub 2000 Jul 6.
Zotero 插件